|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/24 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| C12N 15/13 | (2006.01) | ||
| A61P 37/06 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2514764 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12175103.6 |
| Date of filing the European patent application | 2007-10-18 | |
| (97) | Date of publication of the European application | 2012-10-24 |
| (45) | Date of publication and mention of the grant of the patent | 2019-03-06 |
| (46) | Date of publication of the claims translation | 2019-06-10 |
| (30) | Number | Date | Country code |
| 0620729 | 2006-10-18 | GB |
| (72) |
Adams, Ralph, GB
Popplewell, Andrew George, GB
Rapecki, Stephen Edward, GB
|
| (73) |
UCB Biopharma SRL,
Allée de la Recherche 60, 1070 Brussels,
BE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antikūno molekulės, kurios suriša IL-17A ir IL-17F |
| Antibody molecules which bind IL-17A and IL-17F |
| Payment date | Validity (years) | Amount | |
| 2025-09-19 | 19 | 347.00 EUR |
| 2026-10-18 |